PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.18%
Revenue growth under 50% of ACB.TO's 33.38%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-22.45%
Negative gross profit growth while ACB.TO is at 52.17%. Joel Greenblatt would examine cost competitiveness or demand decline.
-866.94%
Negative EBIT growth while ACB.TO is at 89.31%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-866.94%
Negative operating income growth while ACB.TO is at 32.53%. Joel Greenblatt would press for urgent turnaround measures.
-1775.75%
Negative net income growth while ACB.TO stands at 89.22%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-1785.39%
Negative EPS growth while ACB.TO is at 90.54%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1785.39%
Negative diluted EPS growth while ACB.TO is at 90.54%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
11.26%
Share count expansion well above ACB.TO's 14.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
11.07%
Diluted share count expanding well above ACB.TO's 10.09%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
90.83%
OCF growth above 1.5x ACB.TO's 56.43%. David Dodd would confirm a clear edge in underlying cash generation.
68.66%
FCF growth above 1.5x ACB.TO's 45.52%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
4893.26%
5Y CAGR of 4893.26% while ACB.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
1224.22%
3Y revenue/share CAGR above 1.5x ACB.TO's 255.81%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-1227.10%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
15.30%
Positive OCF/share growth while ACB.TO is negative. John Neff might see a comparative advantage in operational cash viability.
-7393.93%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-5688.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-3007.60%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1597.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
5422.95%
10Y equity/share CAGR above 1.5x ACB.TO's 2633.58%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2128.90%
Below 50% of ACB.TO's 7114.83%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
211.19%
Below 50% of ACB.TO's 506.97%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.46%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
13.05%
Inventory growth well above ACB.TO's 12.18%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.26%
Negative asset growth while ACB.TO invests at 0.98%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-14.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-17.06%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-21.64%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
2.01%
We expand SG&A while ACB.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.